Analysed MOLECULIN BIOTECH INC (MBRX:NASDAQ) News Sources
Moleculin Highlights Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting Highlighting Cardiac Safety Data for Annamycin
21-05-2026
yahoo.com
Moleculin CEO, Walter Klemp, Highlights 45 Subject Enrollment Milestone in Recent Virtual Investor “What This Means” Segment
04-06-2026
yahoo.com
Moleculin Reports Positive Phase 2/3 MIRACLE Interim Results, With Annamycin Complete Remission Rates 3-fold Greater than Control
30-06-2026
yahoo.com
MBRX Stock Drops 25% As Moleculin Biotech's Interim Cancer Trial Data Falls Short Of Significance
30-06-2026
stocktwits.com
Moleculin CEO, Walter Klemp, Highlights Positive Preliminary MIRACLE Trial Results in Virtual Investor "What This Means" Segment
06-07-2026
yahoo.com
Moleculin’s MIRACLE R/R AML Trial Reports Positive Interim Data with 37% Blinded CRc in Venetoclax-Failed Patients
31-07-2026
yahoo.com
Moleculin CEO, Walter Klemp, Participates in the Virtual Investor “Why Now” On-Demand Conference
27-08-2026
yahoo.com
What is the current price of MOLECULIN BIOTECH INC (MBRX:NASDAQ)?
The current price of MOLECULIN BIOTECH INC (MBRX:NASDAQ) is $0.715.
MOLECULIN BIOTECH INC (MBRX:NASDAQ) absolute price change since previous trading day?
The absolute price change of MOLECULIN BIOTECH INC (MBRX:NASDAQ) since the previous trading day is $-0.1149.
MOLECULIN BIOTECH INC (MBRX:NASDAQ) percentage price change since previous trading day?
The percentage price change of MOLECULIN BIOTECH INC (MBRX:NASDAQ) since the previous trading day is -13.845%.
What is the most recent average sentiment score for MOLECULIN BIOTECH INC (MBRX:NASDAQ)?
The most recent average sentiment score for MOLECULIN BIOTECH INC (MBRX:NASDAQ) is 58 out of 100.
What is the most recent average sentiment for MOLECULIN BIOTECH INC (MBRX:NASDAQ)?
The most recent sentiment for MOLECULIN BIOTECH INC (MBRX:NASDAQ) is .
SEC-8K** Filing Available For MOLECULIN BIOTECH INC (MBRX:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.